{"id":5091,"date":"2025-01-17T11:28:42","date_gmt":"2025-01-17T11:28:42","guid":{"rendered":"https:\/\/regensight.com\/ritsight-has-been-issued-the-mdr-ce-certification\/"},"modified":"2025-01-17T11:29:37","modified_gmt":"2025-01-17T11:29:37","slug":"ritsight-has-been-issued-the-mdr-ce-certification","status":"publish","type":"post","link":"https:\/\/regensight.com\/en\/ritsight-ce-certification-mdr\/","title":{"rendered":"RitSight has been issued the MDR CE Certification"},"content":{"rendered":"<p>We are thrilled to announce that <strong>RitSight<\/strong>, our 0.22% riboflavin ophthalmic solution for corneal cross-linking, has been granted the <strong>CE Certificate in conformity with the Medical Device Regulation (MDR)<\/strong>!<\/p>\n<p>This certification marks a significant step forward in advancing corneal cross-linking treatments, ensuring the highest standards of <strong>safety, efficacy, and quality<\/strong> for patients with keratoconus and other corneal disorders, including iatrogenic corneal ectasia, pellucid marginal degeneration, bullous keratopathy and infectious keratitis.<\/p>\n<p>RitSight is designed and manufactured to optimize corneal cross-linking procedures by:<br \/>\n\u2714\ufe0f Offering precise dosing and enhanced bioavailability.<\/p>\n<p>\u2714\ufe0f Supporting personalized treatments through theranostic guided UV therapy.<\/p>\n<p>\u2714\ufe0f Meeting the rigorous requirements of the MDR, reflecting our commitment to innovation and patient care.<\/p>\n<p>We are proud of this achievement, which reinforces our mission to provide cutting-edge solutions for eye health and to support ophthalmologists in delivering the best possible outcomes for their patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>We are thrilled to announce that RitSight, our 0.22% riboflavin ophthalmic solution for corneal cross-linking, has been granted the CE Certificate in conformity with the Medical Device Regulation (MDR)! This certification marks a significant step forward in advancing corneal cross-linking treatments, ensuring the highest standards of safety, efficacy, and quality for patients with keratoconus and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5088,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":""},"categories":[35],"tags":[43,50,94,93],"_links":{"self":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/posts\/5091"}],"collection":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/comments?post=5091"}],"version-history":[{"count":1,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/posts\/5091\/revisions"}],"predecessor-version":[{"id":5092,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/posts\/5091\/revisions\/5092"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/media\/5088"}],"wp:attachment":[{"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/media?parent=5091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/categories?post=5091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regensight.com\/en\/wp-json\/wp\/v2\/tags?post=5091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}